Dolly expert is to clone embryos
By BBC News,
BBC News
| 02. 08. 2005
The creator of Dolly the sheep has been granted a licence to clone human embryos for medical research.
Professor Ian Wilmut and Kings College London scientists will clone early stage embryos to study motor neurone disease (MND).
This is the second time the Human Fertilisation and Embryology Authority has given such permission.
Critics maintain that testing human embryos is immoral. Others question the potential benefits of the work.
Professor Wilmut said it will mean MND can be studied in unprecedented detail.
Therapeutic cloning for research has been legal in the UK since 2001 and it would be only the second time the authority has given consent.
The professor's team was the first to apply for a therapeutic cloning licence in the country.
Up until now, scientists have wanted to create cloned embryos to see if they can be grown into tissues to repair damaged body parts.
But Professor Wilmut's proposal is different as he does not plan to grow healthy replacement tissue.
Instead he aims to deliberately clone embryos that have MND from patients who have the condition.
Professor Wilmut...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
